Vaccines, Blood & Biologics

March 27, 2014 Approval Letter - Typhim Vi

Our STN:BL 103936/5166

Sanofi Pasteur
Attention: Joseph H. Quinn
Discovery Drive
Swiftwater, PA 18370-0187

Dear Mr. Quinn:

We have approved your request to supplement your biologics license application (BLA) for Typhoid Vi Polysaccharide Vaccine (Typhim Vi®) manufactured at your Marcy l’Etoile facility in France, to include revisions to the Typhim Vi® US package insert (USPI) and product (carton and container) labeling. Under this approval, we are agreeing to revisions to the following sections of the USPI: Description, Clinical Pharmacology (Concurrently Administered Vaccines), Drug Interactions, and Adverse Reactions (Data from Clinical Trials and Data From Worldwide Post-Marketing Experience), Warnings, and How Supplied.We are also agreeing to the removal of Current Procedural Terminology (CPT) text from the carton labels and modification of NDC numbers in the USPI and on the container labels.

Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels.In addition, please submit three original paper copies for carton and container final printed labeling. All final labelingshould be submitted as Product Correspondence to this BLAat the time of use (prior to marketing) and include implementation information on FDA Form 356h.

In addition, please submit the final content of labeling (21 CFR 601.14) in SPL format via the FDA automated drug registration and listing system, (eLIST), as described at Information on submitting SPL files using eLIST may be found in the guidance for industry titled, “SPL Standard for Content of Labeling Technical Qs and As at

You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, HFM-602, 1401 Rockville Pike, Rockville, MD 20852-1448. You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that include these changes.

We will include the information contained in the above referenced supplement in your Biologics License Application file.

Sincerely yours,

Wellington Sun, M.D.
Division of Vaccine and Related
Product Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Attachment:Approved Final Draft Labeling

Resources for You

Page Last Updated: 05/11/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.